The EU Vaccine Industry in Figures

Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.

Find out more

Vaccines: a tool for spending smart

Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation

Find out how


Prevention First

Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.

Read more

Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News


European Immunisation Week 2017 – Immunisation at every stage in life

2017 04 24 Written by Vaccines Europe

24-30 April 2017: This week is the European Immunisation Week (EIW2017) that is being celebrated across the European Region. Under the slogan “Vaccines work” the EIW 2017 will focus on the need for and benefits of immunisation at every stage in life.

It is well acknowledged that childhood vaccination is one of the most important medical achievements of the 20th Century. The WHO estimates that vaccination prevents 2-3 million deaths every year across the Globe, and has enormous positive impacts on healthcare systems. However, vaccine-preventable diseases also have significant impacts on adult mortality, health and quality of life. By 2050, the world’s population aged 60 years and older is expected to reach 2 billion, an increase from 900 million today. Increased longevity and lower birth rates are dramatically changing demography in Europe and around the world. With the ageing population, the public health impact of vaccine preventable diseases and their complications in adults are likely to grow.

Over the last few decades there has been a shift in the burden of diseases that were traditionally those of childhood towards older age groups, as explained in the ECDC presentation on “Finding the balance in life-course vaccination” given at the European Health Forum Gastein 2016.

In addition, ageing is associated with a higher prevalence of non-communicable diseases but also with more frequent and severe infections such as diabetes, cardiovascular diseases and chronic obstructive pulmonary disease but also with more frequent and severe infections such as influenza, pneumococcal disease, pertussis and shingles. These diseases may increase the severity of underlying pre-existing chronic diseases and lead to functional decline, loss of autonomy, disability or death and for which comprehensive preventive approaches are key.

For more information visit the WHO Europe website and Twitter profile.

Vaccines Europe welcomes this yearly WHO Europe initiative, and encourages you to share our immunisation related messages.

Vaccines Europe welcomes the appointment of new ECDC Director

2017 03 24 Written by Vaccines Europe

Vaccines Europe welcomes the appointment of Dr. Andrea Ammon as Director of the European Centre for Disease Prevention and Control (ECDC) for the next five years (2017-2022). Vaccines Europe supports a strong leadership role of the ECDC, together with a clear ECDC strategy and vision towards vaccine preventable diseases in Europe.

Global partnership launched to prevent epidemics with new vaccines

2017 01 20 Written by Vaccines Europe

A global coalition to create new vaccines for emerging infectious diseases, was launched on 18th January at the World Economic Forum in Davos, Switzerland. This coalition is funded by the governments of Germany, Japan and Norway, plus the Bill & Melinda Gates Foundation and the Wellcome Trust and supported by several leading vaccine companies.

Please find the official announcement here, and the IFPMA support statement here.

See all News